Study Quantifies Global T2DM, CVD Burdens Attributable to Sugary Drinks
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Jan. 8, 2025 -- Overall, 9.8 percent of all incident type 2 diabetes (T2D) cases and 3.1 percent of incident cardiovascular disease (CVD) cases were attributable to sugar-sweetened beverages (SSBs) worldwide in 2020, according to a study published online Jan. 6 in Nature Medicine.
Laura Lara-Castor, Ph.D., from Tufts University in Boston, and colleagues incorporated data from the Global Dietary Database to estimate SSB-attributed T2D and CVD burdens across 184 countries in 1990 and 2020 globally, regionally, and nationally.
The researchers found that in 2020, 2.2 and 1.2 million new T2D cases and CVD cases, respectively, were attributable to SSBs worldwide, representing 9.8 and 3.1 percent of all incident cases, respectively. Proportional SSB-attributable burdens were higher globally among men than women, for younger than older adults, for higher- than lower-educated adults, and in urban versus rural areas. The highest SSB-attributable percentage burdens were in Latin America and the Caribbean (24.4 percent for T2D and 11.3 percent for CVD) and sub-Saharan Africa (21.5 and 10.5 percent for T2D and CVD, respectively) by world region. Sub-Saharan Africa had the largest proportional increases in SSB-attributable incident T2D and CVD from 1990 to 2020 (+8.8 and +4.4 percent, respectively).
"These findings emphasize the need for targeted interventions, accounting for social inequities and aligned with global health objectives," the authors write. "While some policies to curb SSB intakes are currently in place in some countries, our study suggests that more work is needed."
Several authors disclosed ties to the pharmaceutical and health technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
Increased Risk for CVD Seen for Women With Premenstrual Disorders
THURSDAY, July 17, 2025 -- Women with premenstrual disorders (PMDs) have an increased risk for cardiovascular diseases (CVDs), according to a study published online July 11 in...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.